Curis Inc
$ 0.50
-4.03%
02 Jun - close price
- Market Cap 20,409,200 USD
- Current Price $ 0.50
- High / Low $ 0.54 / 0.50
- Stock P/E N/A
- Book Value 0.66
- EPS -0.58
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.62 %
- ROE -6.94 %
- 52 Week High 3.13
- 52 Week Low 0.46
About
Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$14.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-19 | 2025-11-06 | 2025-08-05 | 2025-05-06 | 2025-03-31 | 2024-11-14 | 2024-08-01 | 2024-05-07 | 2024-02-08 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -1.2497 | -0.4974 | -0.49 | -0.68 | -1.2538 | -1.25 | -1.7 | -2.03 | -2.05 | -2.03 | -2.13 | -0.12 |
| Estimated EPS | -0.29 | -0.4325 | -1.31 | -1.24 | -1.2633 | -0.99 | -1.84 | -1.67 | -2.12 | -2.11 | -2.33 | -0.12 |
| Surprise | -0.9597 | -0.0649 | 0.82 | 0.56 | 0.0095 | -0.26 | 0.14 | -0.36 | 0.07 | 0.08 | 0.2 | 0 |
| Surprise Percentage | -330.931% | -15.0058% | 62.5954% | 45.1613% | 0.752% | -26.2626% | 7.6087% | -21.5569% | 3.3019% | 3.7915% | 8.5837% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRIS
2026-05-22 19:39:34
Curis, Inc. shareholders have approved a significant amendment to its charter, increasing the total authorized capital stock from 288,757,150 to 572,514,300 shares, effectively doubling the authorized common stock. This move expands the company's future equity issuance capacity and simplifies its capital structure by eliminating specific designations for Series A and Series B preferred stock. Additionally, shareholders re-elected two Class III directors, supported executive compensation in a nonbinding vote, and ratified PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year.
2026-05-21 09:08:53
Curis (CRIS), a clinical-stage oncology biotech, is drawing renewed attention from US investors due to recent market coverage highlighting updated Phase 1 data from one of its oncology studies. The article emphasizes that Curis's stock performance is highly sensitive to trial updates and clinical milestones, rather than traditional revenue streams, as it operates in the high-volatility biotech segment of Nasdaq. A recent market news feed reported a significant surge in Curis shares following the data update, underscoring the impact of such catalysts on the stock.
2026-05-20 19:09:21
This article provides the latest news and analysis for Curis Inc. (NASDAQ: CRIS). It includes the current stock price, which is 0.505 USD, and highlights a recent business update from Curis, Inc. 14 days ago regarding their first quarter of 2026 performance. The article functions as a news aggregator from ChartMill.com.
2026-05-20 05:39:34
Five key shareholder proposals, including director elections, executive compensation, auditor ratification, and an increase in authorized shares for Curis, Inc. (CRIS), were approved by a majority vote. The meeting also addressed voting procedures and forward-looking statement risks. This summary is AI-generated based on the company's 2026 AGM audio transcript.
2026-05-16 20:09:06
Curis, a small US biotech, remains focused on advancing its oncology pipeline, particularly its IRAK4 inhibitor emavusertib and PD-1/HDAC inhibitor fimepinostat. Despite a recent reverse stock split to maintain Nasdaq compliance, the company is attracting speculative investors by highlighting progress and safety data in its hematology and oncology programs. Curis emphasizes targeted therapies for genetically defined patient subgroups, relying on collaboration revenue and external financing for its development-stage operations.
2026-05-15 15:39:34
Armistice Capital, LLC and Steven Boyd have filed an Amendment No. 3 to a Schedule 13G/A, disclosing beneficial ownership of 679,033 shares of Curis, Inc. (NASDAQ: CRIS), which represents 4.99% of the company's common stock. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and dispositive power over these shares. The filing indicates a passive investment intent, as the ownership is under 5%.
